Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Osgood

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
JAMA|April 22, 2004
MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomesJames F Trotter, Michael J Osgood
Vascular|October 30, 2012
Cell-permeant peptide inhibitors of vasospasm and intimal hyperplasiaMichael J Osgood, Charles R Flynn, Padmini Komalavilas, et al.
Current Infectious Disease Reports|September 21, 2017
Treatment of Aortic Graft Infection in the Endovascular EraRebecca Sorber, Michael J Osgood, Christopher J Abularrage, et al.
Annals of Vascular Surgery|January 27, 2019
Duplex Ultrasound Assessment and Outcomes of Renal Malperfusion Syndromes after Acute Aortic DissectionMichael J Osgood, Caitlin W Hicks, Christopher J Abularrage, et al.
Journal of Vascular Surgery|October 21, 2016
Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasiaMichael J Osgood, Kevin Sexton, Igor Voskresensky, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 31, 2003
Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejectionMarcelo Kugelmas, Michael J Osgood, James F Trotter, et al.
Journal of Vascular Surgery|August 6, 2013
Surgical vein graft preparation promotes cellular dysfunction, oxidative stress, and intimal hyperplasia in human saphenous veinMichael J Osgood, Kyle M Hocking, Igor V Voskresensky, et al.
Science Translational Medicine|June 12, 2015
MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasiaBrian C Evans, Kyle M Hocking, Michael J Osgood, et al.
The Journal of Surgical Research|July 6, 2012
Intimal thickness associated with endothelial dysfunction in human vein graftsFan Dong Li, Kevin W Sexton, Kyle M Hocking, et al.
JAMA Surgery|September 25, 2014
Brilliant blue FCF as an alternative dye for saphenous vein graft marking: effect on conduit functionIgor V Voskresensky, Eric S Wise, Kyle M Hocking, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
JAMA|April 22, 2004
MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomesJames F Trotter, Michael J Osgood
Vascular|October 30, 2012
Cell-permeant peptide inhibitors of vasospasm and intimal hyperplasiaMichael J Osgood, Charles R Flynn, Padmini Komalavilas, et al.
Current Infectious Disease Reports|September 21, 2017
Treatment of Aortic Graft Infection in the Endovascular EraRebecca Sorber, Michael J Osgood, Christopher J Abularrage, et al.
Annals of Vascular Surgery|January 27, 2019
Duplex Ultrasound Assessment and Outcomes of Renal Malperfusion Syndromes after Acute Aortic DissectionMichael J Osgood, Caitlin W Hicks, Christopher J Abularrage, et al.
Journal of Vascular Surgery|October 21, 2016
Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasiaMichael J Osgood, Kevin Sexton, Igor Voskresensky, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 31, 2003
Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejectionMarcelo Kugelmas, Michael J Osgood, James F Trotter, et al.
Journal of Vascular Surgery|August 6, 2013
Surgical vein graft preparation promotes cellular dysfunction, oxidative stress, and intimal hyperplasia in human saphenous veinMichael J Osgood, Kyle M Hocking, Igor V Voskresensky, et al.
Science Translational Medicine|June 12, 2015
MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasiaBrian C Evans, Kyle M Hocking, Michael J Osgood, et al.
The Journal of Surgical Research|July 6, 2012
Intimal thickness associated with endothelial dysfunction in human vein graftsFan Dong Li, Kevin W Sexton, Kyle M Hocking, et al.
JAMA Surgery|September 25, 2014
Brilliant blue FCF as an alternative dye for saphenous vein graft marking: effect on conduit functionIgor V Voskresensky, Eric S Wise, Kyle M Hocking, et al.
Pageof 2